Global Anthrax Vaccines Market is segmented By Product Type (Cell-Free Vaccines, Live Attenuated Vaccines), By Application (Human Use, Animal Use) By End User (Hospitals, Clinics, Vaccination Centers), By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2024-2031
Anthrax Vaccines Market Size
The Global Anthrax Vaccines Market size was valued at USD million in 2023 and is estimated to reach USD million by 2031, growing at a CAGR of 7.4% during the forecast period (2024-2031). Bacillus anthracis causes anthrax infection is a deadly human disease that also infects livestock as it lives in the soil and is eaten by animals such as sheep, goats and camel antelopes.
Anthrax is transmitted through animals or contaminated animal products, but not from person to person. Anthrax could be used to attack US military personnel during combat.
Anthrax vaccination is the best protection against anthrax. These are commonly given to people at high risk of anthrax infection, such as researchers working with anthrax and military personnel. The anthrax vaccine consists of three doses followed by a booster dose.
Anthrax Vaccines Market Summary
|
Metrics |
Details |
|
Market CAGR |
7.4% |
|
Segments Covered |
By Product Type, By Application, By End User and By Region |
|
Report Insights Covered |
Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights. |
|
Fastest Growing Region |
Asia Pacific |
|
Largest Market Share |
North America |
For More Insights Request Free Sample
Anthrax Vaccines Market Dynamics
The increasing prevalence of infectious diseases like anthrax worldwide, the cost-effectiveness of immunizations, new investment opportunities from government, research foundations and donors, advances in research and manufacturing technologies and increased consumption of undercooked/Raw meat are the factors to drive the market in the forecast period.
The Rising Clinical Trials for Anthrax Vaccines are Expected to Drive Market Growth.
On April 1, 2021, Altimmune, Inc., a clinical-stage biopharmaceutical company, reported clinical data on its NasoShield intranasal anthrax vaccine candidate. The Phase 1b trial evaluated the safety and immunogenicity of one and two-dose regimens of NasoShield in healthy volunteers. The clinical trial was conducted with the Biomedical Advanced Research and Development Authority (BARDA).
Furthermore, On August 24, 2021, BlueWillow Biologics, Inc., a privately held biopharmaceutical company developing intranasal vaccines, announced positive interim results from a Phase 1 clinical trial of its next-generation intranasal anthrax vaccine candidate, BW-1010 Did. BW-1010 combines BlueWillow's patented novel oil-in-water emulsion platform that efficiently presents antigens to the immune system across the nasal mucosa and Porton Biopharma Limited's (PBL) recombinant protective antigen against Bacillus anthracis (RPA). Preliminary data showed that the vaccine administered intranasally two times four weeks apart was safe and well tolerated.
Likewise, BW-1010 induced systemic and mucosal immunity as evidenced by the neutralizing systemic antibodies, nasal IgA/IgG and Th17 responses in peripheral blood cells. This study was funded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), under contract HHSN272201600045C. Thus, from the above factors, the market is expected to drive in the forecast period.
Side Effects Associated With the Anthrax Vaccine are Expected to Hamper Market Growth.
According to the Centers for Disease Control and Prevention, about 1 in 10 people who get the anthrax vaccine have mild pain, redness and swelling at the vaccination site. Also, about 1 in 100 of her vaccinated will develop severe pain and swelling. In addition, 4 of her 7,000 who receive the anthrax vaccine experience brief fevers, chills, body aches or nausea after vaccination.
Severe allergic reactions (called anaphylaxis), such as difficulty breathing, hives and low blood pressure, are extremely rare. Furthermore, the limited availability of vaccines worldwide and stringent regulatory policies are the factors to hamper the market growth in the forecast period.
COVID-19 Impact on Anthrax Vaccines Market
COVID-19 has moderately impacted the anthrax vaccine market. Bacillus anthracis, the causative agent of anthrax, is known to have a worldwide disease burden, especially in mammalian species. For instance, the global concern about the COVID-19 pandemic, anthrax remains a public health concern in Africa.
Anthrax outbreaks have occurred in Zimbabwe and Southern Kenya since March 30, 2021, with high morbidity and low mortality. Sourcing meat from different communities was a common feature in both countries' causality, along with insufficient control, non-functional zoonotic committees and an ineffective coordination response by veterinary and health departments to anthrax outbreaks.
Furthermore, Africa has the lowest capacity to provide critical and intensive care globally. Africa has been plagued by recurring anthrax epidemics affecting animals and people for several years. Some of the programs developed and experiences acquired during past Ebola-affected regions in Africa may have laid the basis for managing the current anthrax epidemic during the COVID-19 pandemic.
Likewise, Countries such as Somalia and Principe, Zambia, Nigeria and Burkina Faso have also hired telecommunications companies to promote the dissemination of information about preventive and control methods. With the assistance of donors and governments, some African countries are also attempting to distribute relief supplies, food and other assistance to the needy.
Despite various efforts to mitigate COVID-19's effects, no uniform early warning system has been established or maintained, particularly for managing anthrax crises during COVID-19, posing life-threatening challenges to animals, humans and the environment. Therefore, the annual vaccination campaign is one of Mozambique's top priorities for preventing and controlling animal disease outbreaks, some of which can be transmitted to humans.
As a result, Mozambique organized a livestock vaccination drive in which 522,972 cattle were immunized against anthrax to prevent uncontrolled animal movement and reduce the risk of complications and contamination among animals and humans. Thus, from the above factors, the market got affected and is expected to improve in the forecast period.
Anthrax Vaccines Market Segment Analysis
The Animal Use Segment is Expected to Hold the Largest Market Share in the Global Anthrax Vaccines Market
The animal use segment accounted for the largest market share in 2021. Anthrax is a disease that can strike quickly, causing death losses in animals with no prior clinical signs. Anthrax is caused by the bacteria Bacillus anthracis, which can form extremely resistant spores in the soil. These spores can survive on pasture for many years and reactivate when the right environmental conditions exist.
Fortunately for cattle producers, anthrax losses can be avoided using a vaccine that has proven effective over time. For instance, the Anthrax Spore Vaccine (Colorado Serum Company) is made up of live, disease-free spores of the B. anthracis bacterium. It is a vaccine that is widely available and reasonably priced through veterinarians. It is approved for use in all domestic farm animals at a subcutaneous dose of 1 cc in the neck. It is extremely safe for animals.
As with most vaccines, animals ideally be vaccinated 2-4 weeks before grazing, but maximum immunity can be achieved in as little as 5-8 days. Therefore, it has increased the demand for anthrax vaccines for animals. Thus, from the above factors, the market segment accounted for the largest market share in the forecast period.
Global Anthrax Vaccines Market Geographical Share
North America Region Holds the Largest Market Share in the Global Anthrax Vaccines Market
North America region accounted for the largest market share in 2021. Owing to the growing number of livestock animals, government initiatives to prevent the spread of anthrax, rising technological advancements in the vaccine and the presence of key players in the region are the factors driving market growth in the forecast period.
For instance, according to the Cattle report published today by the U.S. Department of Agriculture’s National Agricultural Statistics Service (NASS), there was 91.9 million head of cattle and calves on U.S. farms as of January 1, 2022. Moreover, the government initiatives to prevent the spread of anthrax through many ongoing programs under organizations like HHS-CDC, BARDA, ASPR and NIAID.
Furthermore, in Emergent BioSolutions in 2022, revenues from Anthrax vaccines increased by $8.6 million compared to 2021. The increase is largely driven by the timing of deliveries to the U.S. government (USG), specifically the Strategic National Stockpile (SNS). The Company received an AV7909 (Anthrax Vaccine Adsorbed, Adjuvanted) contract modification in September 2021 valued at approximately $399 million to deliver additional AV7909 doses through March 2023. Therefore, it has increased the demand for anthrax vaccines. Thus, from the above factors, the North American region accounted for the largest market share in the forecast period.
Anthrax Vaccines Companies and Competitive Landscape
Major key players in the anthrax vaccines market are Merck & Co., Inc., Emergent Bio-Solutions, Zoetis Inc., PharmaAthene Inc., Biogenesis Bago Inc., Porton Biopharma Inc., Colorado Serum, Sanofi SA, Vecol SA and Panacea Biotec.
Emergent BioSolutions Inc.:
Overview:
Emergent BioSolutions Inc (Emergent) is a life sciences company that provides specialized products to address medical needs and public health threats (PHTs). Its solutions help address PHTs, including chemical, biological, radiological, nuclear and explosives (CBRNE), infectious diseases, travel health, emerging health crises and acute/emergency care. It offers vaccines, therapeutics, drug-device combination products and contract development and manufacturing services.
Emergent's pipeline candidates target dengue and other influenza infections. It also offers specialized products to governments and commercial customers. The company distributes its products in the US and Canada through its commercial sales forces and third-party distributors.
Product Portfolio:
BioThrax (Anthrax Vaccine Adsorbed): BioThrax is the only FDA-licensed vaccine for the prevention of anthrax infection. The FDA licenses it as a pre-exposure prophylaxis for adults at high risk of exposure to anthrax spores. BioThrax is manufactured from a culture filtrate, made from a non-virulent strain of Bacillus anthracis and contains no dead or live bacteria.
The Global Anthrax Vaccines Market Report Would Provide an Access to an Approx. 45+ Market Data Tables, 40+ Figures and 180 Pages.
